An Observational Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Have Previously Received RG-101

Trial Profile

An Observational Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Have Previously Received RG-101

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs RG 101 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Regulus Therapeutics
  • Most Recent Events

    • 10 Oct 2017 Status changed from recruiting to completed.
    • 08 Sep 2017 This study has been completed in Hungary as per European Clinical Trials Database.
    • 12 Jun 2017 According to a Regulus Therapeutics media release, Regulus Therapeutics announced today that it plans to discontinue clinical development of RG-101 upon completion of the one remaining clinical study, which is expected to occur in July 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top